Key result
HeartMate 3 LVAD carries a ~38% incidence of driveline infection over ~16 months.
Observational (n=52)
No
In this single-center cohort of HeartMate 3 LVAD recipients, 38% developed a driveline infection over a median of 15.8 months (predominantly Staphylococcus aureus), highlighting the ongoing burden of device-related infections requiring oral and intravenous antimicrobial therapy.
Answers are grounded in this paper and cite their sources.
Driveline infection risk persists in HeartMate 3 LVAD patients; hypothesis-generating for targeted prevention trials.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Šipuš et al. (2026) conducted an observational in Heart failure supported with HeartMate 3 left ventricular assist device (n=52). HeartMate 3 LVAD support was evaluated on First clinically confirmed driveline infection (DLI). HeartMate 3 LVAD patients had a 38% incidence of first clinically confirmed driveline infection over 15.8 months, with 72.2% infection-free at 1 year and Staphylococcus aureus isolated in 55%.
Synapse has enriched 10 related papers. Consider them for comparative context: